{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:52:46Z","timestamp":1787737966301,"version":"build-2784847793"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s12185-017-2339-5","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T01:24:42Z","timestamp":1507857882000},"page":"373-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia"],"prefix":"10.1007","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9429-1763","authenticated-orcid":false,"given":"Takashi","family":"Ishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Akagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,13]]},"reference":[{"key":"2339_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.05.010","volume":"307","author":"JP Stubgen","year":"2011","unstructured":"Stubgen JP. Drug-induced dysimmune demyelinating neuropathies. J Neurol Sci. 2011;307:1\u20138.","journal-title":"J Neurol Sci"},{"key":"2339_CR2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/106002809603000212","volume":"30","author":"IE Awong","year":"1996","unstructured":"Awong IE, Dandurand KR, Keeys CA, Maung-Gyi FA. Drug-associated Guillain\u2013Barre syndrome: a literature review. Ann Pharmacother. 1996;30:173\u201380.","journal-title":"Ann Pharmacother"},{"key":"2339_CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000052111","volume":"45","author":"FG Meche Van der","year":"2001","unstructured":"Van der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG. Diagnostic and classification criteria for the Guillain\u2013Barre syndrome. Eur Neurol. 2001;45:133\u20139.","journal-title":"Eur Neurol"},{"key":"2339_CR4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"2339_CR5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/jcp.2010.085936","volume":"64","author":"G Chakupurakal","year":"2011","unstructured":"Chakupurakal G, Etti RJ, Murray JA. Peripheral neuropathy as an adverse effect of imatinib therapy. J Clin Pathol. 2011;64:456.","journal-title":"J Clin Pathol"},{"key":"2339_CR6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol"},{"key":"2339_CR7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1759-1961.2010.00015.x","volume":"1","author":"RP Lisak","year":"2010","unstructured":"Lisak RP. Cytokines and chemokines in inflammatory demyelinating neuropathies. Clin Exp Neuroimmunol. 2010;1:153\u201364.","journal-title":"Clin Exp Neuroimmunol"},{"key":"2339_CR8","first-page":"S134","volume":"22","author":"MD Magnano","year":"2004","unstructured":"Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004;22:S134\u201340.","journal-title":"Clin Exp Rheumatol"},{"key":"2339_CR9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/107999000750053690","volume":"20","author":"EP Corssmit","year":"2000","unstructured":"Corssmit EP, de Metz J, Sauerwein HP, Romijn JA. Biologic responses to IFN-alpha administration in humans. J Interferon Cytokine Res. 2000;20:1039\u201347.","journal-title":"J Interferon Cytokine Res"},{"key":"2339_CR10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.1997.269-ce1161.x","volume":"107","author":"EP Corssmit","year":"1997","unstructured":"Corssmit EP, Heijligenberg R, Hack CE, Endert E, Sauerwein HP, Romijn JA. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol. 1997;107:359\u201363.","journal-title":"Clin Exp Immunol"},{"key":"2339_CR11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9343(03)00390-5","volume":"115","author":"I Krause","year":"2003","unstructured":"Krause I, Valesini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003;115:390\u20137.","journal-title":"Am J Med"},{"key":"2339_CR12","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/gast.1997.v112.pm9041265","volume":"112","author":"H Tilg","year":"1997","unstructured":"Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology. 1997;112:1017\u201321.","journal-title":"Gastroenterology"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2339-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T12:54:45Z","timestamp":1519044885000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2339-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,13]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["2339"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2339-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,13]]}}}